JYMed FDA Inspection

Dec 19, 2017

December 2017 – Rochem International is pleased to announce that their strategic manufacturing partner, Shenzhen JYMed Technology Co., Ltd. (JYMed), had a successful FDA inspection in December 2017. In addition to this, JYMed’s Oxytocin Certificate of Suitability (CEP) was recently issued by the European Directorate for the Quality of Medicines (EDQM). JYMed was established in 2009 and is a high-tech enterprise specializing in R&D, manufacturing and commercialization of peptides and related products. Since 2014, Rochem’s Regulatory and Compliance team has worked hand-in-hand with JYMed to ensure that their operations are fully cGMP compliant. Matt Thiel, President of Rochem, stated “This is another important milestone for JYMed and further establishes that they are poised to be a major player in the growing peptides market”.

Related Posts